Title : Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Pub. Date : 2017 Aug

PMID : 28500234






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Niclosamide, a potent inhibitor of AR variants, significantly enhanced bicalutamide treatment. Niclosamide androgen receptor Homo sapiens
2 Niclosamide and bicalutamide combination treatment not only suppressed AR and AR variants expression and inhibited their recruitment to the PSA promoter, but also significantly induced apoptosis in bicalutamide- and enzalutamide-resistant CWR22Rv1 and C4-2B MDVR cells. Niclosamide androgen receptor Homo sapiens
3 Niclosamide and bicalutamide combination treatment not only suppressed AR and AR variants expression and inhibited their recruitment to the PSA promoter, but also significantly induced apoptosis in bicalutamide- and enzalutamide-resistant CWR22Rv1 and C4-2B MDVR cells. Niclosamide androgen receptor Homo sapiens